Pharma Focus Asia
Eppendorf Bioprocess Solutions

A Breakthrough Therapy Discovered for Polycythemia Vera (PV)

Rusfertide, a breakthrough therapy discovered for the treatment of patients with Polycythemia Vera (PV).

Rusfertide reduces the erythrocytosis in those patients who do not require further treatment for thrombocytosis and/or leucocytosis. Rusfertide which is a natural hormone mimeticis supposed to be the first non-cytoreductive therapeutic drug for PV.

Rusfertide in PV is considered to be a serious disease where the need for different and better treatment options is clear and pressing.

Studies have shown patients when treated with rusfertide, were able to eliminate therapeutic phlebotomies and maintain a target hematocrit level of less than 45 percent, reverse iron deficiency, and experience symptom improvements.

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera (PV).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACPHI Korea 2023Bora Pharmaceutical - A robust approach to analytical testing is essentialSelangor International Expo MEDIC 2023TFS - Webinar - DynaSpin™ Single-Use Centrifuge for harvest applicationsMedical Fair Thailand 2023ThermoFisher Scientific - NEW Mobile AppCPHI & PMEC China 20233rd ANNUAL COMPUTER SOFTWARE ASSURANCE 2023Pharma Regulatory Conclave 202320th Anniversary Hospitalog Asia 2023
Charles River Laboratories - Endosafe Compendial LAL Cartridge Technology